Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. As previously disclosed, on April 21, 2026, TuHURA Biosciences, Inc. (the “Company”) entered into a Loan Agreement (the “Loan Agreement”) with Parkview Holdings One LLC, as lender. The Loan Agreement provides for a revolving credit facility that matures on April 21, 2031, with a maximum amount of loan availability of $50 million. On September 2, 2026, the Company received and bor…

Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. As previously disclosed, on April 21, 2026, TuHURA Biosciences, Inc. (the “Company”) entered into a Loan Agreement (the “Loan Agreement”) with Parkview Holdings One LLC, as lender. The Loan Agreement provides for a revolving credit facility that matures on April 21, 2031, with a maximum amount of loan availability of $50 million. On August 20, 2026, the Company received and borro…

Unregistered Sale of Equity Securities . As previously disclosed in the Current Report on Form 8-K filed by TuHURA Biosciences, Inc. (the “Company”) with the Securities and Exchange Commission on April 22, 2026, on April 21, 2026, the Company entered into a Loan Agreement (the “Loan Agreement”) with Parkview Holdings One LLC (“Parkview”), under which Parkview agreed to extend a $50 million revolving credit facility to the Company. In connection with the Loan Agreement, pursuant to a Fee Lette…

Results of Operations and Financial Condition. On August 14, 2026, TuHURA Biosciences, Inc. issued a press release reporting its financial results for the three months ended June 30, 2026, and providing a corporate update. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated by reference herein. The information contained in this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is being furnished, shall not be deemed “filed” for any purpose, and…

Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. As previously disclosed, on April 21, 2026, TuHURA Biosciences, Inc. (the “Company”) entered into a Loan Agreement (the “Loan Agreement”) with Parkview Holdings One LLC, as lender. The Loan Agreement provides for a revolving credit facility that matures on April 21, 2031, with a maximum amount of loan availability of $50 million. On August 7, 2026, the Company received and borrow…

Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. As previously disclosed, on April 21, 2026, TuHURA Biosciences, Inc. (the “Company”) entered into a Loan Agreement (the “Loan Agreement”) with Parkview Holdings One LLC, as lender. The Loan Agreement provides for a revolving credit facility that matures on April 21, 2031, with a maximum amount of loan availability of $50 million. On July 28, 2026, the Company received and borrowe…

Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. As previously disclosed, on April 21, 2026, TuHURA Biosciences, Inc. (the “Company”) entered into a Loan Agreement (the “Loan Agreement”) with Parkview Holdings One LLC, as lender (“Parkview”). The Loan Agreement provides for a revolving credit facility that matures on April 21, 2031, with a maximum amount of loan availability of $50 million. On May 26, 2026, the Company received…

Results of Operations and Financial Condition. On May 15, 2026, TuHURA Biosciences, Inc. (the “Company” or “TuHURA”) issued a press release reporting its financial results for the three months ended March 31, 2026, and providing a corporate update. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated by reference herein.

Entry into a Material Definitive Agreement. On April 21, 2026, TuHURA Biosciences, Inc. (the “Company”) entered into a Loan Agreement (the “Loan Agreement”) with Parkview Holdings One LLC, as lender (“Parkview”), under which Parkview agreed to extend a $50 million revolving credit facility to the Company upon the terms and conditions set forth in the Loan Agreement. The Company intends to use borrowings under the Loan Agreement for general corporate purposes, including the funding of the Comp…

The Company claims an exemption from the registration requirements of the Securities Act of 1933, as amended (the “Securities Act”), for the private placement of the Loan Fee Shares and Conversion Shares, as the Loan Fee Shares and Conversion Shares will be issued solely to “accredited investors,” as such term is defined in the Securities Act of 1933, as amended (the “Securities Act”), and in reliance on the exemption from registration afforded by Section 4(a)(2) and/or Regulation D (Rule 506…

Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. The information provided in

The filing details compensation adjustments and bonuses for existing executives.

Results of Operations and Financial Condition. On April 1, 2026, TuHURA Biosciences, Inc. (the “Company” or “TuHURA”) issued a press release reporting its financial results for the year ended December 31, 2025, and providing a corporate update. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated by reference herein The information contained in this Current Report, including Exhibit 99.1 attached hereto, is being furnished, shall not be deemed “filed” for any pur…

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On January 29, 2026, TuHURA Biosciences, Inc. (the “Company”) received a letter from The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company’s consolidated closing bid price has been below $1.00 per share for 35 consecutive business days as of January 28, 2026, and that, therefore, the Company is not in compliance with Nasdaq Listing Rule 5550(a)(2), which is the minimum bid price r…

Entry into a Material Definitive Agreement. Securities Purchase Agreement On December 9, 2025, TuHURA Biosciences, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with certain investors (collectively, the “Purchasers”). The Purchase Agreement relates to the sale and issuance in a registered direct offering (such sale and issuance, the “Offering”), by the Company of an aggregate of: (i) 9,462,423 shares of the Company’s common stock, par value $0.00…

Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. The information set forth under

Entry into a Material Definitive Agreement. Amendment to Secured Promissory Note and Loan Agreement As disclosed in a Current Report on Form 8-K filed by TuHURA Biosciences, Inc. (the “Company”) on October 31, 2025, the Company previously entered into a Secured Promissory Note and Loan Agreement, dated October 27, 2025 (the “Loan Agreement”), with the Matthew Nachtrab Revocable Trust dated 12/18/2014 (the “Lender”). Pursuant to the terms of the Loan Agreement, the Lender agreed to make loans…

Regulation FD Disclosure. On November 22, 2025, TuHURA Biosciences, Inc.’s (the “Company”) Registration Statement on Form S-3 (File No. 333-291239) (the “Shelf Registration Statement”) initially filed with the Securities and Exchange Commission (the “SEC”) on November 3, 2025, became effective in accordance with the provisions of Section 8(a) of the Securities Act of 1933, as amended (the “Securities Act”). As previously disclosed, on June 2, 2025, the Company completed its private placement…

Results of Operations and Financial Condition. On November 14, 2025, TuHURA Biosciences, Inc. (the “Company” or “TuHURA”) issued a press release reporting its financial results for the three months ended September 30, 2025, and providing a corporate update. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated by reference herein The information contained in this Current Report, including Exhibit 99.1 attached hereto, is being furnished, shall not be deemed “filed…

Entry into a Material Definitive Agreement. Bridge Loan Transaction On October 27, 2025, TuHURA Biosciences, Inc. (the “Company”) entered into a Secured Promissory Note and Loan Agreement (the “Loan Agreement”) with the Matthew Nachtrab Revocable Trust dated 12/18/2014 (the “Lender”). Pursuant to the terms of the Loan Agreement, the Lender agreed to make loans to the Company in an aggregate principal amount of up to $3,000,000 (the “Loans”) during a 30-day availability period beginning on the…

Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. The information set forth under

Entry into a Material Definitive Agreement. As previously announced, on June 2, 2025, TuHURA Biosciences, Inc. (the “Company”) and investors (the “Purchasers”) entered into a securities purchase agreement (the “Securities Purchase Agreement”) pursuant to which the Company agreed to issue to the Purchasers, in a private placement (the “Offering”), an aggregate of 4.76 million shares (the “Shares”) of the Company’s common stock, par value $0.001 per share (“Common Stock”), together with warrant…

Results of Operations and Financial Condition. On August 14, 2025, TuHURA Biosciences, Inc. issued a press release reporting its financial results for the three months ended June 30, 2025, and providing a corporate update. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated by reference herein The information contained in this Current Report, including Exhibit 99.1 attached hereto, is being furnished, shall not be deemed “filed” for any purpose, and shall not be…

The filing details compensation adjustments and bonuses for existing executives, not a management change.

Entry into a Material Definitive Agreement. On June 2, 2025, TuHURA Biosciences, Inc. (the “Company”) and investors (the “Purchasers”) entered into a securities purchase agreement (the “Securities Purchase Agreement”) pursuant to which the Company agreed to issue to the Purchasers, in a private placement (the “Offering”), an aggregate of 4.76 million shares (the “Shares”) of the Company’s common stock, par value $0.001 per share (“Common Stock”), together with warrants to purchase an equal nu…